Free Trial
NYSE:PRGO

Perrigo Q2 2025 Earnings Report

Perrigo logo
$27.20 -0.06 (-0.22%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$27.21 +0.01 (+0.04%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo EPS Results

Actual EPS
N/A
Consensus EPS
$0.59
Beat/Miss
N/A
One Year Ago EPS
N/A

Perrigo Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.08 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Perrigo Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 1, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Perrigo Earnings Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Perrigo (NYSE:PRGO) Cut to "Hold" at Wall Street Zen
PRGO - Perrigo Co PLC Chart - Morningstar
See More Perrigo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email.

About Perrigo

Perrigo (NYSE:PRGO) is a leading global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals. The company develops, manufactures and distributes a broad portfolio of branded and private-label products spanning pain relief, digestive health, vitamins, minerals and supplements, infant formulas, and women’s health. Perrigo’s offerings are sold through supermarket chains, pharmacies, mass merchandisers, and healthcare providers under both its own labels and those of retail partners.

Founded in 1887 in Allegan, Michigan, Perrigo has grown from a regional supplier to a global healthcare manufacturer by combining organic innovation with strategic acquisitions. In 1999, Perrigo re-domiciled to Ireland, establishing a presence in Europe and positioning itself to expand into new markets. Over the decades, Perrigo has integrated manufacturing facilities, R&D centers and distribution networks in the United States, Europe, the Middle East and Africa, allowing the company to serve more than 100 countries worldwide.

The company operates four key business segments: Consumer Self Care–North America, Consumer Self Care–International, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients (APIs). Its North America arm focuses on store-brand OTC and nutritional products, while the international segment supplies branded and private-label products across Europe, the Middle East and emerging markets. Perrigo’s prescription division concentrates on generic pharmaceuticals, delivering cost-effective alternatives to branded drugs, and its API unit manufactures key chemical components for both internal use and external customers.

Perrigo is led by President and Chief Executive Officer Eyal Desheh and supported by a seasoned executive team with experience in pharmaceuticals, consumer goods and global supply chain management. The board emphasizes quality, regulatory compliance and innovation, investing in new product development and digital capabilities to enhance customer engagement. With a commitment to affordability, accessibility and consumer well-being, Perrigo continues to expand its footprint in core markets while pursuing strategic growth opportunities across the healthcare landscape.

View Perrigo Profile

More Earnings Resources from MarketBeat